ArticleLiver cancer2026
Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Correspondence to letter to the editor on "Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features".Clinical and molecular hepatology · 2026Article
- Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma.Liver cancer · 2026Article
- [Research progress on poor response, resistance mechanisms, and influencing factors of immunotherapy for hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Introduction: The development of targeted therapies and immune checkpoint inhibitors for advanced hepatocellular carcinoma (HCC) reinforces the need for individualized treatment. However, precision medicine is hindered by the lack of mandatory tissue biopsy for genomic profiling in HCC. Liquid biopsy enables genomic profiling of circulating tumor DNA (ctDNA), which could compensate for the lack of tissue-based analysis. This study evaluated the concordance between ctDNA and tumor tissue genomic profiling and its feasibility in advanced HCC treated with atezolizumab plus bevacizumab (atezo/bev). Methods: This cohort study prospectively collected pretreatment plasma samples from 130 patients with advanced HCC who underwent tissue-based sequencing before systemic therapy from June 2020 to October 2022. Tumor tissue sequencing was performed using the Oncomine Comprehensive Assay, and ctDNA sequencing was conducted using Guardant360. Results: ctDNA variants revealed 72.6% (69/95; 95% CI, 62.9-80.6%) sensitivity and 75.0% (69/92; 95% CI, 65.3-82.7%) positive predictive value compared to tumor tissue. With an interval of ≤30 days between ctDNA and tumor tissue sampling, the sensitivity increased to 96.3% (26/27; 95% CI, 81.7-99.3%). In patients treated with first-line atezo/bev, maximum variant allele frequency (maxVAF) of ctDNA was significantly correlated with poor survival outcomes even after adjustment for clinicogenomic variables. Conclusion: In advanced HCC, ctDNA-based genotyping demonstrated clinically acceptable concordance with tissue-based profiling, providing a reliable alternative when tissue samples are limited. Additionally, ctDNA maxVAF demonstrated independent prognostic value in patients treated with first-line atezo/bev. Liquid biopsy using ctDNA can help address challenges associated with limited tissue-based genomic profiling in advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.